Loading...
Loading...
PTIXW| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 12.6K |
| Gross Profit | -12.6K |
| Operating Expense | 1,654.8K |
| Operating I/L | -1,667.3K |
| Other Income/Expense | 60.8K |
| Interest Income | 9.3K |
| Pretax | -1,606.5K |
| Income Tax Expense | -0.0K |
| Net Income/Loss | -1,606.5K |
Protagenic Therapeutics, Inc. is a pre-clinical biopharmaceutical company specializing in the discovery and development of therapeutics for stress-related neuropsychiatric and mood disorders. Their lead compound, PT00114, is a synthetic form of teneurin carboxy-terminal associated peptide, designed to dampen overactive stress responses. The company's revenue model is based on the development and commercialization of these therapeutics, with a focus on addressing unmet medical needs in the treatment of stress-related neuropsychiatric and mood disorders.
